Context: Determination of arginine vasopressin (AVP) concentrations may be helpful to guide therapy in critically ill patients. A new assay analyzing copeptin, a stable peptide derived from the AVP precursor, has been introduced.
Objective: Our objective was to determine plasma copeptin concentrations.
Design: We conducted a post hoc analysis of plasma samples and data from a prospective study.
Setting: The setting was a 12-bed general and surgical intensive care unit (ICU) in a tertiary university teaching hospital.
Patients: Our subjects were 70 healthy volunteers and 157 ICU patients with sepsis, with systemic inflammatory response syndrome (SIRS), and after cardiac surgery.
Interventions: There were no interventions.
Main Outcome Measures: Copeptin plasma concentrations, demographic data, AVP plasma concentrations, and a multiple organ dysfunction syndrome score were documented 24 h after ICU admission.
Results: AVP (P < 0.001) and copeptin (P < 0.001) concentrations were significantly higher in ICU patients than in controls. Patients after cardiac surgery had higher AVP (P = 0.003) and copeptin (P = 0.003) concentrations than patients with sepsis or SIRS. Independent of critical illness, copeptin and AVP correlated highly significantly with each other. Critically ill patients with sepsis and SIRS exhibited a significantly higher ratio of copeptin/AVP plasma concentrations than patients after cardiac surgery (P = 0.012). The American Society of Anesthesiologists' classification (P = 0.046) and C-reactive protein concentrations (P = 0.006) were significantly correlated with the copeptin/AVP ratio.
Conclusions: Plasma concentrations of copeptin and AVP in healthy volunteers and critically ill patients correlate significantly with each other. The ratio of copeptin/AVP plasma concentrations is increased in patients with sepsis and SIRS, suggesting that copeptin may overestimate AVP plasma concentrations in these patients.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1210/jc.2005-2830 | DOI Listing |
Alzheimers Res Ther
January 2025
Center for Cognitive and Computational Neuroscience, Complutense University of Madrid, Pozuelo de Alarcón, 28223, Spain.
Background: Changes in amyloid beta (Aβ) and phosphorylated tau brain levels are known to affect brain network organization but very little is known about how plasma markers can relate to these measures. We aimed to address the relationship between centrality network changes and two plasma pathology markers: phosphorylated tau at threonine 231 (p-tau231), a proxy for early Aβ change, and neurofilament light chain (Nfl), a marker of axonal degeneration.
Methods: One hundred and four cognitively unimpaired individuals were divided into a high pathology load (33 individuals; HP) group and a low pathology (71 individuals; LP) one.
BMC Vet Res
January 2025
Department of Veterinary Sciences, Veterinary Teaching Hospital "Mario Modenato", University of Pisa, via Livornese snc, San Piero a Grado, Pisa, Italy.
Background: Current endogenous indicators utilised in avian medicine are not sensitive enough to detect renal disease in its early stages. Alternative markers ought to be examined as a result. The aim is to investigate the accuracy of limited-sampling models for glomerular filtration rate (GFR) in adult seagulls using plasma clearance of iohexol (IOX).
View Article and Find Full Text PDFHomozygous MTAP deletion occurs in ~15% of cancers, making them vulnerable to decreases in the concentration of S-adenosylmethionine (SAM). AG-270/S095033 is an oral, potent, reversible inhibitor of methionine adenosyltransferase 2 A (MAT2A), the enzyme primarily responsible for the synthesis of SAM. We report results from the first-in-human, phase 1 trial of AG-270/S095033 as monotherapy in patients with advanced malignancies (ClinicalTrials.
View Article and Find Full Text PDFLuminescence
January 2025
Pharmaceutical Analytical Chemistry Department, Faculty of Pharmacy, Al-Azhar University, Cairo, Egypt.
In this study, a sensitive and selective spectrofluorimetric method was developed for the determination of the antidiabetic drug nateglinide based on its reaction with the xanthene dye acid red 87 (AR87). A fluorescence quenching process was observed for the AR87 at 545 nm upon the addition of nateglinide, which was exploited for the quantitative analysis. The reaction mechanism was investigated using quantum mechanical calculations suggesting a transfer between the electron-rich AR87 and the electron-deficient nateglinide.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!